The evolving role of lenalidomide in the treatment of hematologic malignancies. - Wikidata - wikimedia - TriplyDB

The evolving role of lenalidomide in the treatment of hematologic malignancies.

The evolving role of lenalidomide in the treatment of hematologic malignancies.

http://www.wikidata.org/entity/Q36739807

about

Current and emerging treatment options for patients with relapsed myeloma Immunomodulatory agents in myelofibrosis.Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.Expanding role of lenalidomide in hematologic malignancies A Validated Stability-Indicating and Stereoselective HPLC Method for the Determination of Lenalidomide Enantiomers in Bulk Form and Capsules.Novel anti-myeloma agents and angiogenesis.Lenalidomide and its role in the management of multiple myeloma.Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.Choosing treatment options for patients with relapsed/refractory multiple myeloma.Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma Distribution of lenalidomide into semen of healthy men after multiple oral doses.Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?

P2860

Q26830878-26278891-1F7D-436B-9CF5-4B62970B1835 Q33401615-A2698AB1-D773-40F3-8EAA-6D1370FC2CAC Q33973877-14AF0378-0530-4544-8A6A-A323E7461F66 Q34611491-0F54C208-3378-4B22-A71D-D6EBE710FDD2 Q35592305-48BE0F1A-B6BD-4BDB-8739-3F2539BB64E2 Q36960501-913FBD0B-B2CF-4E9C-A648-072DF761204D Q37132903-2BEECD80-EE0E-49C7-9093-D5BAFA75C9CB Q37183439-B440087A-C361-4740-AD82-424551747B1D Q37991783-3970C323-239B-4198-852E-A632CA656A54 Q38170453-F37B79F0-D014-4EE1-AD9F-FECDF3ABE58F Q39305248-7B6E09E4-2B02-429E-8D88-BF490FBAD50F Q43160182-349E72FE-F60A-40C0-A383-3CAC3D407655 Q43726973-2D2E1E5C-8FC4-4B62-972D-D97FBC3D9FE2 Q46859906-2B57F577-7363-42F8-B901-4A72882B7B4F

P2860

The evolving role of lenalidomide in the treatment of hematologic malignancies.

http://www.wikidata.org/entity/Q36739807

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

The evolving role of lenalidomide in the treatment of hematologic malignancies.

@ast

The evolving role of lenalidomide in the treatment of hematologic malignancies.

@en

type

label

The evolving role of lenalidomide in the treatment of hematologic malignancies.

@ast

The evolving role of lenalidomide in the treatment of hematologic malignancies.

@en

prefLabel

The evolving role of lenalidomide in the treatment of hematologic malignancies.

@ast

The evolving role of lenalidomide in the treatment of hematologic malignancies.

@en

P1433

Q36739807-5DA040C8-22D6-4DF4-A26E-CEDBC13D699C

P1476

Q36739807-AA5FC012-464E-463C-B6D9-8ADED9BE42EB

P2860

Q36739807-01CA26BA-D97A-4CDB-8F64-077919790B4A

Q36739807-09E73F51-2154-40E7-8D00-49011EEDD224

Q36739807-0A928902-56C6-431B-91CB-3DB9EAA52E59

Q36739807-153984CB-4D1A-49B4-9EA6-D8EA3E55199D

Q36739807-1908269C-9980-4CFF-9F03-BC28877C6D79

Q36739807-1BD954B6-9366-4810-AB5E-6E628E05D760

Q36739807-1F5A5CAC-AF0D-48BB-9F97-4F60947E4A4A

Q36739807-2A201184-0C1B-432C-97EB-D3827A764C0E

Q36739807-2CCBAC5E-D8F7-41D4-A8E1-F143C79EDAA0

Q36739807-2F5F8476-94F8-43B7-AA5F-FF103BA96940

P304

Q36739807-C0D35737-6E0D-4F5C-B7E4-DA44C0B18AFC

P31

Q36739807-D96E3914-3388-4C14-AAA3-E7876BEF920B

P356

Q36739807-E37F9B16-85C4-49DC-846E-676A2900A5D4

P407

Q36739807-80246981-CC80-4D4E-96ED-7C9AEDD115DD

P433

Q36739807-5F933B31-EF45-4BBB-9025-BBB19D606747

P478

Q36739807-08F0A976-32AD-448C-93FD-06D4EA8E69E0

P50

Q36739807-0073EE95-A297-468E-AF73-191AD2883030

Q36739807-48F3A958-BAE4-444F-96FE-EAB38969D511

P577

Q36739807-6F4C1C3D-E839-4FF3-A2BB-3D65AE9E4601

P698

Q36739807-55C6782B-6C3C-44FA-9711-6ED84229D0CD

P356

14656566.8.4.497

P1433

Expert Opinion on Pharmacotherapy

P1476

The evolving role of lenalidomide in the treatment of hematologic malignancies.

@en

P2860

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

Chronic lymphocytic leukemia

Proposals for the classification of the myelodysplastic syndromes

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Efficacy of lenalidomide in myelodysplastic syndromes.

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

P304

497-509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.8.4.497

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

Efstathios Kastritis

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17309344

http://www.w3.org/2001/XMLSchema#string